Posted by Michael Wonder on 08 Nov 2021
Why does the FDA want to stop improving medicines via patent ‘areas of concern’?
8 November 2021 - It’s hardly unprecedented for one federal agency to encroach on another’s turf. But the latest intra-executive-branch dustup is particularly eyebrow-raising.
This fall, acting FDA Commissioner Janet Woodcock wrote a letter to the U.S. Patent and Trademark Office to share “areas of concern” about patents issued for prescription medications.
